Moreover, VSP inhibition may trigger hypertension via microvascular rarefaction, reducing vessel density, or functional rarefaction, heightening vasomotor tone and limiting blood flow.476 Recent studies also link VSP inhibitors to salt-sensitive hypertension through interstitial sodium buildup and osmotic stress, especially in the skin.477–479 This complex interplay between VEGF signaling, endothelial function, and blood pressure highlights challenges in managing anti-VEGF therapy-induced hypertension, warranting further research for effective strategies. The gene discussed is VEGFA; the disease is Hypertension.